Administering Treprostinil to an Intubated Patient Kristen Merriman, MS, RRT-ACCS, RRT-NPS, AE-C, RCP Director of Cardiopulmonary & Neurodiagnostic Services Good Samaritan Hospital, San José, CA

Rationale Inhaled treprostinil (Tyvaso ® ) is FDA approved for treatment of pulmonary hypertension

Rationale Inhaled treprostinil (Tyvaso ® ) is FDA approved for treatment of pulmonary hypertension One unit dose (2.9 mL) is used each day

Rationale Inhaled treprostinil (Tyvaso ® ) is FDA approved for treatment of pulmonary hypertension One unit dose (2.9 mL) is used each day Patient takes four treatments each day

Rationale Inhaled treprostinil (Tyvaso ® ) is FDA approved for treatment of pulmonary hypertension One unit dose (2.9 mL) is used each day Patient takes four treatments each day Proprietary ultrasonic nebulizer

Rationale

Methods Four 1 mL syringes used to draw up 0.75 mL doses

Methods Four 1 mL syringes used to draw up 0.75 mL doses Aerogen nebulizer

Methods

Results Transient decrease in mean pulmonary arterial pressure (40 mm Hg  36 mm Hg)

Results Transient decrease in mean pulmonary arterial pressure (40 mm Hg  36 mm Hg) SpO 2 increase (91%  96%)